ArticleCancers2020
Intronic
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- The TP53 gene contains a diversity box that makes it more than a tumor suppressor.Cell death and differentiation · 2026Review
- Associative memory plays a role in ER-1α positive breast cancers.Cell death and differentiation · 2026Review
- Regulatory Variants in the KRAS 3'UTR and Intron 2 Are Associated with Breast Cancer Susceptibility Through Independent and Combinatorial Effects in a Mexican Population.Biomedicines · 2026Article
- Review
- Identification of Genes Associated with the Pan-Vibrios Resistance (PVR) Trait of Pacific White Shrimp (Biology · 2026Article
- Systemic exosome abundance and comprehensive proteome profile of lymphoma-derived exosomes: Insights into host-tumor interactions.Medical oncology (Northwood, London, England) · 2025Article
- Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma.Cell death discovery · 2025Article
- Genetic association and functional implications of AhR gene polymorphism on preeclampsia.Frontiers in cardiovascular medicine · 2025Article
- The Association ofInternational journal of molecular sciences · 2024Article
- p53 isoform expression promotes a stemness phenotype and inhibits doxorubicin sensitivity in breast cancer.Cell death & disease · 2023Article
- p53 Dysregulation in Breast Cancer: Insights on Mutations in theInternational journal of molecular sciences · 2023Article
- Association ofBiomedicines · 2023Article
- Association of Interactions between Metabolic 'Caretaker' Genes, p53, MDM2, and Tobacco Use with the Risk of Oral Cancer: A Multifactor Dimensionality Reduction Approach.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Cytoplasmic p53β Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer.International journal of molecular sciences · 2022Article
- Adaptive homeostasis and the p53 isoform network.EMBO reports · 2021Review
- Chromatin loop anchors predict transcript and exon usage.Briefings in bioinformatics · 2021Article
- Association between Predicted Effects ofInternational journal of molecular sciences · 2021Article
- Review
- The Δ133p53 Isoforms, Tuners of the p53 Pathway.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 2 countries.
Ramona A EiholzerDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Sunali MehtaDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0002-1777-1245
Marina KazantsevaDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0001-7267-0036
Catherine J DrummondDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Cushla McKinneyDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0002-7051-6876
Katie YoungDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
David SlaterPriority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
Brianna C MortenPriority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
Kelly A Avery-KiejdaPriority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
Annette LashamDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland 1023, New Zealand.ORCID 0000-0002-1084-4261
Nicholas FlemingDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Helen R MorrinDepartment of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand.
Karen ReaderDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0002-5253-0666
Janice A RoydsDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0003-1464-2197
Michael LandmannDepartment of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Simone PetrichDepartment of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Roger ReddelChildren's Medical Research Institute, University of Sydney, Westmead, New South Wales 2145, Australia.ORCID 0000-0002-6302-6107
Lily HuschtschaChildren's Medical Research Institute, University of Sydney, Westmead, New South Wales 2145, Australia.
Ahmad TahaDepartment of Neurosurgery, Southern District Heath Board, Dunedin 9016, New Zealand.
Noelyn A HungDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
Tania L SlatterDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.ORCID 0000-0003-4031-0604
Antony W BraithwaiteDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
University of Otago · NZMaurice Wilkins Centre · NZHunter Medical Research Institute · AUThe University of Sydney · AUMalaghan Institute of Medical Research · NZSouthern District Health Board · NZUniversity of Auckland · NZ
Funding
Australian Cancer Council NSW PG11-08Cancer Institute NSW CDF181205Cancer Society of New Zealand Drummond 18.11Health Research Council CDA Slatter 16/054Health Research Council of New Zealand 15/500HRC Emerging First Researcher Grant Mehta 20/638Marsden Fund UOO1903
Abstract
We investigated the influence of selected
Indexed as
glioblastomaprostate cancerrs1042522rs9895829 and rs2909430single nucleotide polymorphismTP53Δ133p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.